New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools by Muñoz Galván, Sandra et al.
RESEARCH Open Access
New markers for human ovarian cancer
that link platinum resistance to the cancer
stem cell phenotype and define new
therapeutic combinations and diagnostic
tools
Sandra Muñoz-Galván1,2†, Blanca Felipe-Abrio1,2†, Miguel García-Carrasco3, Julia Domínguez-Piñol1,
Elisa Suarez-Martinez1, Eva M. Verdugo-Sivianes1,2, Asunción Espinosa-Sánchez1, Lola E. Navas1,
Daniel Otero-Albiol1,2, Juan J. Marin1,2, Manuel P. Jiménez-García1,2, Jose M. García-Heredia1,2,4,
Adoración G. Quiroga5, Purificacion Estevez-Garcia1,2,3 and Amancio Carnero1,2*
Abstract
Background: Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to a late
diagnosis and a high rate of recurrence. Primary and acquired platinum resistance is related to a low response
probability to subsequent lines of treatment and to a poor survival. Therefore, a comprehensive understanding of
the mechanisms that drive platinum resistance is urgently needed.
Methods: We used bioinformatics analysis of public databases and RT-qPCR to quantitate the relative gene expression
profiles of ovarian tumors. Many of the dysregulated genes were cancer stem cell (CSC) factors, and we analyzed its
relation to therapeutic resistance in human primary tumors. We also performed clustering and in vitro analyses of
therapy cytotoxicity in tumorspheres.
Results: Using bioinformatics analysis, we identified transcriptional targets that are common endpoints of genetic
alterations linked to platinum resistance in ovarian tumors. Most of these genes are grouped into 4 main clusters related
to the CSC phenotype, including the DNA damage, Notch and C-KIT/MAPK/MEK pathways. The relative expression of
these genes, either alone or in combination, is related to prognosis and provide a connection between platinum
resistance and the CSC phenotype. However, the expression of the CSC-related markers was heterogeneous in the
resistant tumors, most likely because there were different CSC pools. Furthermore, our in vitro results showed that the
inhibition of the CSC-related targets lying at the intersection of the DNA damage, Notch and C-KIT/MAPK/MEK pathways
sensitize CSC-enriched tumorspheres to platinum therapies, suggesting a new option for the treatment of patients with
platinum-resistant ovarian cancer.
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Conclusions: The current study presents a new approach to target the physiology of resistant ovarian tumor cells
through the identification of core biomarkers. We hypothesize that the identified mutations confer platinum resistance by
converging to activate a few pathways and to induce the expression of a few common, measurable and targetable
essential genes. These pathways include the DNA damage, Notch and C-KIT/MAPK/MEK pathways. Finally, the combined
inhibition of one of these pathways with platinum treatment increases the sensitivity of CSC-enriched tumorspheres to
low doses of platinum, suggesting a new treatment for ovarian cancer.
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Background
Ovarian cancer (OC) is the seventh most frequent malig-
nant tumor type in women worldwide and is the leading
cause of death from gynecological cancer, accounting for
4% of cancer-related deaths (GLOBOCAN) [1]. The ma-
jority of patients are diagnosed at an advanced stage due
to unspecific clinical manifestations. There are 4 main
histologic subtypes that have been described: serous (ap-
proximately 70%), endometrioid, clear cell and mucinous.
In recent years, evidence has shown that there are unique
molecular features, treatment responses and prognoses
for each of the subtypes. Genetic alterations involving
DNA homologous recombination repair system (BRCA1/
2, genes of the Fanconi anemia and DNA mismatch repair
pathways) are the most investigated and have been identi-
fied in more than 30% of OCs. Other relevant alterations
include defective Notch, PI3K, RAS-MEK and forkhead
box protein M1 (FOXM1) signaling pathways, as well as
mutations in TP53, MTOR or MYC in high-grade serous
or endometrioid OCs, mutations in ARID1A, PIK3CA and
PTEN in clear-cell carcinomas, and KRAS, BRAF or
CDKN2A mutations in mucinous carcinomas [2].
Complete cytoreductive surgery that achieves the resec-
tion of all macroscopically visible disease is a major factor
that determines the chances of success in the treatment of
OC. Chemotherapy is always given after surgery since most
of the patients will eventually relapse, except in cases of
nonaggressive tumors and in very early stage tumors. Plat-
inum agents constitute the most active group of chemo-
therapy drugs in ovarian cancer, and over the last decades,
multiple studies have progressively optimized the efficacy
and tolerability of the treatment. Combination schemes of
cisplatin and taxanes demonstrated a higher survival bene-
fit over monotherapy and other combinations, and the cis-
platin analogue carboplatin confirmed similar efficacy and
substantially better tolerance than cisplatin. Therefore,
intravenous carboplatin in combination with paclitaxel
every 3 weeks constitute the standard first-line treatment
for OC [3]. Pegylated liposomal doxorubicin [4, 5] or doce-
taxel [6] are alternatives for patients who are not candidates
for paclitaxel, and these treatments showed similar efficacy
with a different toxicity profile. More recently, targeted
therapies directed against angiogenesis (bevacizumab) and
PARP inhibitors have demonstrated benefit in ovarian can-
cer, expanding available therapeutic options [2].
The clinical response rates to these drugs regularly ex-
ceed 60%, and the median time to the onset of recurrence
usually exceeds 1 year even in the subset of women with
suboptimal cytoreduction [2, 7–9]. In spite of surgery and
chemotherapy administration, approximately 80% of the
patients will relapse. Recurrent disease is generally incur-
able, and it is classified as platinum-resistant (recurrence <
6 months after last platinum dose) or platinum-sensitive (>
6 months). Platinum-resistant o sensitive status is one of
the most important prognostic factors in recurrent disease
and it is also a predictive factor of response of retreatment
with platinum-based schemes. Platinum-resistant tumors
show dismal outcomes with median overall survival less
than 12 months [3]. Therefore, the search for new com-
pounds that may be active in platinum-resistant tumors
(primary or acquired after treatment) is a necessity for these
patients. In addition, the identification of platinum response
biomarkers would help to discriminate patients, avoiding
the administration of high doses of cytotoxic compounds
to patients who would not obtain a real benefit.
Many mutations have been found to be responsible for
the resistance to platinum drugs (TCGA, [7, 10–15]), al-
though their complexity makes the analysis of ovarian
cancer resistance difficult. We hypothesize that the many
known mutations that confer platinum resistance are
distributed among different pathways, which may activate
a few common essential effector genes. Ultimately, these
effector genes may be responsible for the “ovarian cancer
resistance physiology”, which may be measurable, predict-
ive and targetable.
In this study, we performed a bioinformatic analysis
with public databases to analyze transcriptional alterations
that were common in ovarian tumors, mainly linked to re-
currence. It was hypothesized that these alterations were
causally connected to resistance to platinum therapy.
After individual validation, the data suggest that these
genetic alterations are involved in the acquisition of stem-
ness properties that are linked to the resistance to therapy
in ovarian tumor cells. Finally, the inhibition of key regula-
tors of the stemness phenotype can recover sensitivity to
platinum in stem cell surrogate assays.
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Methods
Study approval
Written informed consent was provided by all patients. This
project was approved by the Research Ethics Committee of
the Hospital Universitario Virgen del Rocio (CEI 0309-N-
15). All tissue samples and patient information were treated
in accordance with the Declaration of Helsinki.
Patient cohort
A cohort of paraffin-embedded tissue samples from 21
patients with ovarian cancer were obtained from the bio-
bank of the Hospital Universitario Virgen del Rocío-
Instituto de Biomedicina de Sevilla (Sevilla, Spain) for
RNA expression studies and for a correlation analysis of
the clinicopathological features. Samples were obtained
from biopsies of patients subjected to platinum treat-
ment who were evaluated for their response according
to the RECIST criteria, and normal tissue, platinum-
resistant and platinum-sensitive tumor samples were
obtained. Tumor samples were sent to the pathology
laboratory for diagnosis and were prepared for storage
with formalin fixation and paraffin embedding. Samples
were stained with hematoxylin/eosin, and RNA was
extracted and obtained from tumor tissue.
Public databases of clinical samples
To validate our results, we obtained data from publicly
available clinical and genomic databases, including Onco-
mine (https://powertools.oncomine.com/) and the TCGA
Research Network (http://cancergenome.nih.gov/).
RT–qPCR
Total RNA from paraffin-embedded tissue samples was
purified using a Recover All Total Nucleic acid isolation
Kit (Invitrogen) according to the manufacturer’s instruc-
tions, but with slight modifications; specifically, digestion
was performed for 3 h at 50 °C and 15 min at 80 °C. Total
RNA from tumorspheres and total adherent cultured cells
(total culture samples) was purified using a ReliaPrepTM
RNA Tissue Miniprep System (Promega, Fitchburg, WI,
USA) according to the manufacturer’s instructions. Reverse
transcription was performed with 0.5 μg of mRNA using a
High-Capacity cDNA Reverse Transcription C-KIT (Life
Technologies) according to the manufacturer’s recommen-
dations. The PCR mixture (10 μl) contained 2 μl of the
reverse transcription reaction product diluted 1:6, 2.5 μl of
water, 5 μl of GoTaqR Probe qPCR Master Mix (Promega)
and 0.5 μl of the appropriate TaqMan Assay (20X) contain-
ing primers and a probe for the mRNA of interest (Applied
Biosystems). We used the following probes (Applied Bio-
systems): ADRB3 (Hs_00609046_m1), ANG (Hs04195574_
s1), BTG2 (Hs00198887_m1), ESD (Hs00382667_m1),
FBXL7 (Hs00202348_m1), RAD51 (Hs00947967_m1), ST
13 (Hs00832556_s1), ST7L (Hs00373316_m1), DUSP4
(Hs01027785_m1), AP1M2 (Hs01091817_m1), CKAP4
(Hs_00199135_m1), C-KIT (Hs00174029_m1), DUSP1 (Hs
00610256_g1), PAX8 (Hs01015257_g1), NOTCH3 (Hs01
128541_m1), CD133 (Hs01009257_m1), NANOG (Hs042
60366_g1), CXCR4 (Hs00607978_s1), ABCG2 (Hs010
53790_m1) and GAPDH (Hs03929097_g1). We analyzed
the quality of RNA obtained from the tumor samples and
normalized expression levels to the housekeeping gene
GAPDH.
Cell culture
Cells were cultured according to the manufacturer’s rec-
ommended procedure. Briefly, SKOV3 and OVCAR8
were cultured in RPMI and incubated at 37 °C with 5%
CO2 in a humidified atmosphere.
Tumorsphere assay
Cells were washed once with PBS and then harvested
with 0.025% trypsin-EDTA. A total of 5 × 103 cells of
each cell line were resuspended in 1 ml of complete
MammoCult medium (contains the MammoCult Basal
medium, MammoCult Proliferation Supplement, fresh
hydrocortisone and heparin; STEMCELL Technologies)
and seeded in ultralow attachment 24-well plates (Corn-
ing #3473). Cultures were incubated in a 5% CO2 hu-
midified incubator at 37 °C for 4 days. Tumorspheres
were then visualized by inverted microscopy (Olympus
IX-71) and were counted. Experiments were independ-
ently repeated a minimum of three times in triplicate.
Cytotoxic MTT assay
A total of 5 × 103 SKOV3 or OVCAR8 cells were seeded
to form tumorspheres and then treated 24 h later with
platinum drugs or/and Notch or C-KIT inhibitors
(DATP or imatinib, respectively). After 96 h, the cell
viability was measured with MTT.
Quantification and statistical analysis
All statistical analyses were performed using GraphPad
Prism 4. The distribution of quantitative variables
among different study groups was assessed using para-
metric (Student’s t-test) or nonparametric (Kruskal–
Wallis or Mann–Whitney) tests, as appropriate. Experi-
ments were performed a minimum of three times and
were always performed as independent triplicates. Sur-
vival data from the patient databases were analyzed with
the log-rank Mantel-Cox statistical test.
Analyses of cancer patient databases
We performed meta-analyses of the PrognoScan public
patient datasets (http://dna00.bio.kyutech.ac.jp/PrognoS-
can/) to analyze the expression levels in tumor and non-
tumor databases for ovary tissue samples. Statistical sig-
nificance versus normal samples was considered to be
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P < 0.05. Patient survival was analyzed using the R2
Genomics analysis and visualization platform (http://
hgserver1.amc.nl), developed by the Department of
Oncogenomics of the Academic Medical Center (AMC)
(Amsterdam, Netherlands). Kaplan-Meier plots showing
patient survival were generated for databases with avail-
able survival data using the scan method, which search
for the optimum survival cut-off based on statistical ana-
lyses (log-rank test), thus finding the most significant ex-
pression cut-off. To analyze the protein network, we use
the web portal https://string-db.org.
Results
Identification of biomarkers for poor prognosis in ovarian
tumors
We performed an analysis of publicly available transcrip-
tional datasets (Additional file 1: Table S1) to identify
genes whose expression may be highly deregulated
(levels of transcription > 4-fold higher or < − 4-fold
lower than the mean of the non-tumor samples) in ovar-
ian tumors. In these datasets, the most represented
tumor type was serous adenocarcinoma, although differ-
ent ovarian tumor subtypes were discriminated in differ-
ent datasets. We compared the mRNA levels in tumors
with the mRNA levels in normal ovarian tissue and
found genes that were up- or down-regulated with clear
statistical significance (P < 0.01) (Table 1). Among the
upregulated genes in the tumors compared to those in
the normal tissue, we found CKAP4, DUSP1, PAX8,
AP1M2, C-KIT and NOTCH3, with NOTCH3 being the
only gene that was upregulated in all tumor types. PAX8
and C-KIT were upregulated in most tumor types, while
CKAP4 and DUSP1 were upregulated only in serous and
mucinous adenocarcinoma. Interestingly, AP1M2 was
highly upregulated exclusively in clear cell carcinoma
compared to normal tissue. On the other hand, 9 genes
were found to be downregulated in tumor vs nontumor
tissue (Table 1). ST13 was commonly downregulated in all
tumor types compared to normal tissue. Compared to the
expression levels in normal tissue, other genes, such as
ADRB3, BTG2, DUSP4, RAD51 or FBLX7, were downreg-
ulated in specific tumor types, and ANG, ESD and STL7
were downregulated in most tumor types. In general, the
highly deregulated genes in ovarian tumors have a very
wide range of functions, families and chromosomal loci.
Next, we analyzed the mutational profile of these genes
in ovarian cancer using the TCGA database on cBioportal.
We did not observe any clear mutational profile among
those genes, except for C-KIT (Additional file 1: Table S2).
However, most of the genes showed clear chromosomal
alterations (either amplification or deletions) and clear
mRNA alterations (Additional file 1: Table S2). In general,
these alterations correlated well with the observed pattern
of behavior found in ovarian tumors. The analysis of
promoter methylation indicated that most genes showed a
methylation pattern that was compatible with the expres-
sion data (Additional file 1: Figure S1).
Thus far, we have identified genetic alterations whose
further confirmation may reveal possible diagnostic rele-
vance. To test this, we analyzed the repercussions of these
Table 1 Upregulated or downregulated genes found in ovary tumors vs non-tumoral ovary tissue
Serous Adc Mucinous Endometroid Carcinoma Clear Cell C. Gene definition
Upregulated
CKAP4 CKAP4 Cytoskeleton associated protein 4
DUSP1 DUSP1 Dual specificity phosph atase 1
AP1M2 Adaptor-rela ted protein complex1,
Mu2 subunit
PAX8 PAX8 PAX8 PAX8 Paired box 8
NOTCH3 NOTCH3 NOTCH3 NOTCH3 NOTCH3 Notch homolog 3
C-KIT C-KIT C-KIT Mast cell growth factor receptor
Downegulated
ADRB3 ADRB3 Adrenergic B3 receptor
ANG ANG ANG ANG Angiogenin
BTG2 BTG family member 2
DUSP4 DUSP4 Dual specifi city phosph atase 4
FBXL7 FBXL7 F-Box and leucin rich rep eat protein 7
ESD ESD ESD ESD Esterase D
ST13 ST13 ST13 ST13 ST13 Suppressor of tumors 13
ST7L ST7L ST7L Suppressor of tumors 7 like
RAD51 BRCA1/BRCA2-containing complex, subunit 5
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alterations in regard to the survival probability of ovarian
cancer patients using different public transcriptomic data-
sets. Cox analysis of the mRNA levels of the upregulated
genes showed that patients expressing high levels of
NOTCH3, CKAP4, PAX8 and AP1M2 had a significantly
shorter survival than patients with low expression levels of
these genes. We found the same trend for DUSP1 and
C-KIT, but with no statistical significance (Fig. 1a).
On the other hand, the analysis of the downregulated
genes showed that low levels of BTG2, DUSP4, FBXL7,
ST13 and ST7L were significantly associated with a shorter
survival of the patients compared to those expressing high
levels of these genes (Fig. 1b). Similarly, low expression
levels of ADRB3, RAD51, ANG and ESD showed a clear
tendency toward shorter survival but without statistical
significance (Fig. 1b).
Finally, we analyzed all deregulated genes in combination
and generated high- and low-risk groups with the Cox
regression analysis. We used mRNA expression levels in
the 4 databases with the highest numbers of patients of
those analyzed above. The resulting Kaplan-Meier curves
showed that the high-risk combinations of these 15 genes
were clearly predictive of a worse prognosis (Additional file
1: Figure S2A). In addition, the expression levels of the
genes of study in those high and low risk groups followed
in general the same trend than those in the individual
analyses. The analysis of the different stages also showed a
clear and significantly lower survival probability for patients
with the high-risk gene combination in all stages of the
TCGA ovarian cystadenocarcinoma cohort compared to
that of the low-risk group (Additional file 1: Figure S2B).
Clustering analysis of the identified genes related to
ovarian resistance
Platinum-based chemotherapy constitutes the backbone
of systemic treatment in ovarian cancer, and platinum re-
sistance represents a major prognostic factor for shorter
event-free latency and lower survival compared to plat-
inum-sensitive disease (Additional file 1: Figure S3).
Therefore, the prognostic capabilities of the genes found
in our meta-analysis, as well as the pathways involved, will
be likely to predict the response to platinum therapies in
ovarian tumors.
The identified genes are associated with a broad
spectrum of activities (Table 1), and it is difficult to assign
common functions that may be related to the phenotype
of therapy resistance. To shed light on the pathways in-
volved in platinum resistance, we used a network-based
approach, overlaying the information from the differential
gene expression analysis onto protein interaction networks
and subnetworks using the string interaction network por-
tal (https://string-db.org).
Most of the grouping analyses with all genes recog-
nized DNA damage and repair pathways, based only on
the Rad51 gene (Additional file 1: Figure S4A), or the
Adaptor-related protein complex 1 group of genes,
based only on AP1M2. Other clusters around group 1,
which contained the rest of the genes, were always
grouped into three or four main clusters. The NOTCH
pathway and the MAPK/MEK pathway, involving C-KIT,
which was either related or not to the AKT/pathway,
were found in all network combinations (Additional file
1: Figure S4B). On the other hand, some network combi-
nations formed a cluster around Yamanaka’s factors
(NANOG, SOX2, KLF4 and POU5F1), which were
connected through MYC, STAT3, NOTCH3 and C-KIT
(Additional file 1: Figure S4C). Other genes, such as
ASD, FBL7, ST7L or ADRB, were not significantly con-
nected to the main clusters in most of the combinations.
Although this analysis was not conclusive, these results
may indicate that the DNA damage, MAPK/AKT (in-
volving C-KIT), and the NOTCH pathways are recur-
rent, major networks that formed with the combination
of the alterations found in our screenings. In addition,
these networks have been repeatedly reported to support
the CSC phenotype in ovarian tumors [16–22].
The previous data indicate two possible experimental
hypotheses: first, the genes found in our screening may
be altered in cultures that are enriched for CSCs and
may therefore be markers of CSC enrichment in ovarian
tumors; second, these “core” networks, the MAPK/AKT
(involving C-KIT), NOTCH and DNA damage pathways,
may be ideal therapeutic targets to recover platinum
sensitivity. We will address both hypotheses in the fol-
lowing experiments.
Relevance of CSCs in resistance to platinum
The existence of ovarian CSCs were reported more than
10 years ago, and ovarian CSCs have been reported to
be responsible for resistance to chemo- and radiotherapy
[17, 20, 23–26]. Based on these reported data, we ex-
plored whether cancer stem cells (CSCs) were enriched
for our newly identified gene set. For this purpose, we
seeded tumorspheres, which are supposed to be enriched
in CSCs [22, 27–31], and compared their gene expres-
sion to that of mature cells from tumor cell lines in cul-
ture. To this end, we seeded cells from the ovarian
cancer cell lines SKOV3 and OVCAR8 in CSC media
and in low attachment plates to form tumorspheres.
Once the tumorspheres had formed, we extracted RNA
from the total adherent cell culture and from tumor-
spheres. We observed that the expression of the genes
AP1M2, CKAP4, DUSP1, c-KIT, PAX8 and NOTCH3
shows a statistically significant increase in expression in
tumorspheres from at least one of the cell lines (Fig. 2a;
Additional file 1: Figure S5A). On the other hand, ANG,
BTG2, ESD, FBXL7, ST13 and ST17L are down-
regulated in tumorspheres from both cell lines, while
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DUSP4 and RAD51 are only down-regulated in those
from OVCAR8 cells. These data suggest that the expres-
sion of genes related to resistance in ovarian tumors are
related to the stemness phenotype.
Then, as a control, we evaluated the expression of the
CSC-related genes in tumorspheres. We observed, com-
pared to the levels expressed by the adherent cell lines, that
tumorspheres generated from both cell lines expressed
significantly higher levels of ALDH1, CD133, NANOG,
CXCR4 and ABCG2 (Fig. 2b; Additional file 1: Figure S5B),
which have been proposed to be markers of ovarian CSC
population [17, 20, 23–26].
Predictive value for the response to cisplatinum
The data so far suggested that the stemness acquired by
tumors is ultimately responsible for therapeutic resistance
Fig. 1 Analysis of the survival probability of ovarian cancer patients in different datasets by the expression of the identified genes. Cox analysis of
survival probability of patients according to mRNA levels of different genes. Kaplan-Meier curves of the genes up-regulated (a) or down-
regulated (b) in ovarian cancer
Muñoz-Galván et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:234 Page 6 of 14
in ovarian tumors [16–22]. To confirm this hypothesis, we
examined the expression of stemness-related genes in
primary tumor samples. For this study, we used sam-
ples from platinum-resistant and platinum-sensitive
ovarian tumors.
Hence, we sought to determine whether the identified
genes could predict resistance to platinum drugs in primary
samples from resistant tumors. Samples were obtained
from the biopsies of ovarian cancer patients who under-
went platinum-based chemotherapy, and the tumor
response was assessed. Nonresponding subjects were iden-
tified, and the tumors were analyzed. A few nontumor sam-
ples from ovaries were also obtained and included as
controls (Additional file 1: Table S3).
The analysis of gene expression showed that, at a glo-
bal level, c-KIT was significantly up-regulated in resist-
ant vs. sensitive patients, while DUSP4 was significantly
down-regulated (Fig. 3a-b; Additional file 1: Figure S6).
Analysis of individual patients showed a number of them
whose expression was also de-regulated, such as AP1M2,
PAX8, C-KIT and NOTCH3. These genes showed very
low levels of expression in non-tumor and platinum-
sensitive tumor tissue, and a large increase in the ex-
pression levels was observed in some resistant tumors.
For the down-regulated genes, high decreases in the
expression were also observed in some individual pa-
tients for ADRB3, FBXL7, RAD51, ST13 and ST7L (Fig.
3b; Additional file 1: Figure S6). However, a high hetero-
geneity was observed among the analyzed genes, and it
was difficult to assign a specific “resistance” effect to the
different genes (Fig. 3a), both for the up- and down-
regulated ones. It is worth noting that the analysis of the
proportion of resistant patients showing expression
levels above or under the median value of the sensitive
ones showed significant alterations of this proportion for
DUSP1, c-KIT, NOTCH3, ANG, BTG2R, DUSP4, FBXL7
and ST13 (Fig. 3c), indicating that they are commonly
de-regulated in platinum-resistant patients.
In this platinum (Pt)-resistant vs Pt-sensitive cohort,
we measured the levels of the CSC-related genes
ALDH1, CD133, ABCG2, CXCR4 and NANOG. We
found that the Pt-resistant tumors expressed higher
levels of these genes than the Pt-sensitive tumors (Fig. 4),
indicating that the stemness capacity was higher in the
Pt-resistant tumors than in the Pt-sensitive tumors. In
addition, we also observed a large amount of heterogen-
eity among the different resistant samples (Fig. 4), pos-
sibly indicating that the resistance was provided by
different redundant pathways or by different pools of
CSCs with different characteristics.
Fig. 2 Gene expression analyses in tumorspheres from ovarian cancer cell lines. a Gene expression analyses by RT-qPCR of up- and down-regulated
genes in tumorspheres and total adherent cell culture (total culture) samples from SKOV3 and OVCAR8 ovarian cancer cell lines. b Gene expression
analyses by RT-qPCR of C-KIT, CD133, NANOG, CXCR4 and ABCG2 in tumorspheres and total culture samples from SKOV3 and OVCAR8 ovarian cancer
cell lines. For (a) and (b), normalized expression values of tumorspheres compared to total culture samples (line at value 1) are shown. The average
and SD of three independent experiments are shown. Statistical significance was assessed using the one-sample t-test. *, P < 0.05; **, P < 0.01; ***,
P < 0.001
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Fig. 3 (See legend on next page.)
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Sensitization to platinum drugs by inhibiting cancer
stemness-related pathways
Since resistance is dependent on the CSC phenotype, we
hypothesized that the inhibition of these CSC networks
might sensitize ovarian cancer cells to platinum treat-
ments. To confirm this hypothesis, we seeded both of
the tumor ovarian cell lines to form tumorspheres and
treated them with suboptimal doses of cisplatin (IC30;
0.3 μM) or carboplatin (IC30; 0.3 μM) (Fig. 5 and Add-
itional file 1: Figure S7) alone or in combination with
suboptimal doses of inhibitors of the stem cell-related
genes from our profile (Additional file 1: Table S4), such
as DAPT (5 μM), a NOTCH inhibitor whose target is γ-
secretase, imatinib (8 μM), a C-KIT inhibitor, PD98059
(15 μM), a MAPK inhibitor, and BEZ235 (10 μM), a
PI3K inhibitor. We also treated the tumorspheres with
platinum in combination with the PARP inhibitor
olaparib (10 μM). In all cases, we used concentrations
that did not reduce significantly the number or the size
of the tumorspheres (Fig. 5).
We observed that the used doses of cis- or carboplati-
num alone did not affect the survival or the number of
tumorspheres, as with each of the targeted inhibitors
alone (Fig. 5). However, treatment with the targeted in-
hibitors greatly reduced the number of tumorspheres in
both cell lines when they were used in combination with
cisplatin or carboplatin (Fig. 5) compared to that of the
controls. In all cases, the combinations provided a sig-
nificant reduction of approximately 50% in the number
of tumorspheres compared to controls. Furthermore, the
inhibition of the DNA damage pathway was slightly
higher with the combination with both platinums com-
pared to that of the other inhibitors, while DAPT, a
NOTCH inhibitor, had lower activity in combination
with carboplatin compared to the other inhibitors.
In the end, these data suggest that combinations of plat-
inum drugs with C-KIT, MAPK, PI3K or PARP inhibitors
may be a suitable therapy to avoid recidiva or metastasis in
ovarian tumors or for the treatment of platinum-resistant
tumors.
Discussion
The cytotoxic activity of platinum complexes produces
DNA alterations and increases the oxidative levels in
tumor cells. This cytotoxic activity causes intra- and in-
terstrand crosslinks and the formation of DNA adducts,
provoking conformational changes that impair DNA rep-
lication. On the other hand, the increase of ROS species
may induce DNA and mitochondrial damage, leading to a
decrease in ATP activity. In addition, platinum-derived
compounds produce alterations in cellular transport.
Therefore, genetic events that alter any of these mecha-
nisms may limit the efficacy of platinum compounds. Many
mutations or alterations of the methylation profiles and epi-
genetic signals are involved in platinum resistance (TCGA
database, cBioportal) [10–13, 32]. In addition, a recent ana-
lysis of a large number of patients with high-grade serous
ovarian tumors showed a high degree of complexity, a high
number of genomic aberrations and genetic alterations, and
high levels of intra- and intertumoral heterogeneity [33–
35]. Hence, the use of these alterations, most of them oc-
curring with a very low frequency, as biomarkers to predict
sensitivity or resistance to platinum-derived compounds is
not currently useful. Since resistance to platinum treat-
ments is one of the main causes of poor survival among
ovarian cancer patients, the identification of prognostic and
predictive biomarkers, as well as the understanding of the
mechanisms driving resistance, is urgently needed.
We identified transcriptional targets that are possibly
the common endpoints of the genetic alterations that are
linked to platinum resistance in ovarian tumors. We found
15 genes that were transcriptionally altered, 6 of which
were overexpressed and 9 of which were downregulated,
belonging to different families. Compared to that in nor-
mal tissue, CKAP4, DUSP1, PAX8, NOTCH3, C-KIT and
AP1M2 were upregulated in tumor tissue, while ADRB3,
ANG, BTG2, ESD, ST13, ST7L, RAD51, DUSP4 and
FBXL7 were highly downregulated in tumor tissue. Indi-
vidually, most of these genes showed prognostic value in
terms of overall survival in ovarian cancer patients, where
platinum-derived compounds are still the main therapy.
The genes that did not show statistically significant differ-
ences still showed a clear trend in our analysis. On the
other hand, the complete profile of all of the genes also
showed a clear predictive capability for the prognosis of
overall survival or relapse-free survival, independent of
the tumor stage. This profile itself could be used to stratify
patients due to its predictive value for platinum resistance.
It would also be interesting to combine our profile with
other clinical predictors, such as CA125, stage, histological
type or the degree of differentiation, to provide an accur-
ate clinical assessment with increased prognostic and
(See figure on previous page.)
Fig. 3 Gene expression analyses and platinum resistance in tumoral samples from ovarian cancer patients. a Gene expression analyses by RT-
qPCR of the candidate up-regulated genes in non-tumoral and tumoral samples from ovarian cancer patients, resistant or sensitive to platinum
treatment. b Same analysis as in (a) with the down-regulated genes in ovarian cancer. For (a) and (b), the average and SD of three independent
experiments are shown. c Proportion of platinum-resistant patients with expression levels for each gene above (Up) or below (Down) the median
value of the sensitive ones. Statistical significance was assessed using the Fisher’s exact test by comparison with the proportions of sensitive
patients. *, P < 0.05, ***, P < 0.001
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predictive value that could help to stratify patients in clin-
ical practice.
Numerous attempts have been made to identify signa-
tures associated with ovarian cancer therapy resistance
[16, 33–41]. Most of the multiple signature limitations
involve the number of cases, representability of the dif-
ferent tumor types, further analysis of treatments, etc. A
few of these signatures underwent further gene regula-
tory network analysis, identifying a unique network of
genes that may potentially support current clinical prac-
tice, similar to our study. For example, Chudasama et al.
found two proteins, RAD51AP1 and FSTL1, that were
significantly overexpressed in ovarian cancer samples
[36]. In our study, we observed the downregulation of
RAD51 in tumor samples, which may account for the
RAD51AP1 increase. Liu et al. reported a list of 21 genes
from a literature search that may be involved in ovarian
cancer drug resistance [33–35]. One of these genes was
NOTCH3, which was also identified in our analysis.
Interestingly, 8 of the genes from that study are a part of
our network (FOS, JUN, BCL2, KRAS, MAPK1, MYC,
NOTCH3 and STAT3), and most of the other genes are
directly related to genes with similar functions to those
found in our network (Bad and Bax are related to BCL2;
EGFR and ERBB2 are receptor Ser/thr kinases that are
related to Ras and the MAPK pathway; and Src, PIK3CA
and AKT are also related to the Ras/MAPK pathway). It
is important to take into account that most of the
markers that have been proposed were related to the
molecular mode of action of platinum, either preceding
binding, directly related to the formation of adducts or
related to the activation of the signaling pathway that is
induced by DNA damage [11]. A small number of
markers represented off-target effects that are not related
to the mechanism of action of platinum at any level; only
one of our 15 markers may be directly related to the DNA
signaling pathways, RAD51, while the rest represent off-
target effects. Interestingly, the MAPK pathway is at the
core of our network and has been repeatedly described in
the literature [10, 11, 33–35]; therefore, the MAPK path-
way may represent one of the main targets that could be
leveraged to overcome platinum resistance. Our data on
the cytotoxicity of suboptimal doses of the treatments on
the tumorspheres suggest that combinations of platinum
drugs with C-KIT, MAPK, PI3K or DNA-damage inhibi-
tors may be a suitable therapeutic strategy to increase
Fig. 4 Gene expression analyses and platinum resistance in tumoral
samples from ovarian cancer patients. Gene expression analyses by
RT-qPCR of C-KIT, CD133, NANOG, CXCR4 and ABCG2 in non-tumoral
and tumoral samples from ovarian cancer patients, resistant or sensitive
to platinum treatment. The average and SD of three independent
experiments are shown. Statistical significance was assessed using the
Student’s t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001
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activity, avoid recidiva or the metastasis of platinum-
resistant ovarian tumors.
We confirmed that the transcriptional levels of the
genes found in our meta-analysis were also altered in sam-
ples from patients with platinum-resistant tumors from
our own patient cohort, reinforcing their value as prog-
nostic markers. Furthermore, we also found increased
levels of CSC markers in the samples from platinum-
resistant patients, connecting the resistance to platinum
treatment to the CSC phenotype. We think that the CSC
phenotype also has a clear prognostic value. The analysis
of the CSC-related genes that were identified in our work
(ALDH1, CD133, NANOG, CXCR4 and ABCG2) showed
that outside of their relevance for defining the CSC
phenotype, these genes have no relevant prognostic value,
either alone or as a group (data not shown). This lack of
prognostic value is probably due to the large amount of
heterogeneity that was observed in the expression of these
genes in human tumors. However, our profile of 15 genes,
which are not mechanistically related to the mechanism of
action of cisplatin and are related to the off-target resist-
ance signaling pathways [11], have a clear prognostic
ability to identify patients with ovarian tumors who are
likely to develop resistance to platinum therapy.
Network analysis of these genes showed that most of
the genes are integrated into 4 main clusters, three of
which are linked directly to stemness. These networks are
the NOTCH network, the MEK/MAPK network and,
especially, the Yamanaka core (NANOG, SOX2, OCT4 and
KLF4). These networks are connected through C-KIT,
STAT3, NOTCH1 and MYC. These 4 genes lie at the mid-
dle of the three stemness networks and may be essential
nodes to explore for therapeutic interventions.
Multiple markers, such as the Hoechst side population,
CD133+, CD117 (c-KIT)+, ALDH1+ or CD44+ cells, have
been described and used to identify CSCs from ovarian tu-
mors [16–22]. However, the concept of the ovarian CSC is
controversial and has not been properly demonstrated. A
unique CSC population has not been described, and it has
not been concluded whether CSCs are responsible for
ovarian cancer resistance. Some markers, such as CD133+,
CXCR4+ [42] or ALDH1 + CD133+ [21], also define differ-
ent CSC populations in ovarian tumors. In some cases, as
in CD133+/CXCR4+ cells, these populations are also
Fig. 5 Notch, C-KIT, MAPK, PI3K and PARP inhibition reduces tumorsphere formation in ovary tumor cells. a Tumorsphere formation in OVCAR8
and SKOV3 cells treated with cis-platin (IC30; 0.3 μM), with or without gamma-secretase inhibitor DAPT (5 μM), tyrosine kinase inhibitor Imatinib
(8 μM), PARP inhibitor olaparib (10 μM), MAPK inhibitor PD98059 (15 μM) or PI3K inhibitor BEZ235 (10 μM). b Tumorsphere formation in OVCAR8
and SKOV3 cells treated with carboplatin (IC30; 0.3 μM), with or without the inhibitors described in (A). The average and SD of at least three
independent experiments are shown. Statistical significance was assessed using the Student’s t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001
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related to an increased expression of the stemness tran-
scriptional core, SOX2, OCT4, KLF4 and NANOG [42]. It
has also been suggested that the expression of some of
these markers depends on the environmental conditions
[21]. These data agree with the apparent heterogeneity of
the CSC markers that was present in different resistant tu-
mors, which probably reflects the selection of one of the
different subpopulations, but each of these markers are re-
lated to the physiology of CSCs [43–49]. However, a
complete demonstration has not been provided. Our work
directly analyzed 15 genes that were identified with tran-
scriptional screening, 3 of which are directly related to
stemness (NOTCH3, C-KIT and PAX8) and 5 of which
were direct markers of CSCs (ALDH1, ABCG2, CXCR4,
CD133 and NANOG) in ovarian tumor samples from
platinum-resistant patients, corroborating this relation-
ship. All of these data suggest that these CSC markers
are not mutually exclusive and that they may appear as
a result of multiple genetic changes that occur during
the process of tumorigenesis.
The heterogeneity of the different CSC markers found
among the resistant tumors was remarkable (Fig. 4). The
correlation among the different markers indicated that
different CSC populations may have been present. Most of
the CSC markers correlated with ALDH1, and we also
found some correlation between CXCR4 and CD133
(Additional file 1: Figure S8), suggesting a general CSC
population was represented by ALDH1, and that there
was a CXCR4 + CD133 subpopulation, as has been
previously reported [21, 42]. However, these trends also
presented some heterogeneity. This may indicate that
resistance is provided by different redundant pathways or
by different pools of CSCs, most likely with distinct char-
acteristics. Whether these pathways or CSC pools have
different features and how this translates into the hetero-
geneity of the tumors needs to be further explored.
As previously mentioned, the networks that we identi-
fied are connected through C-KIT/MAPK/AKT or
NOTCH. These genes lie at the middle of the networks
and may be essential nodes that could be used to explore
novel therapeutic interventions. In fact, we tested
whether their inhibition produced any effect on CSC re-
sistance. Our data showed that the inhibition of any of
these nodes at suboptimal doses in combination with
cisplatin or carboplatin significantly reduced the growth
of the tumorspheres, elements that are enriched for
CSCs. On the other hand, we expect much better results
upon the inhibition of more than one node of the path-
way, and this should preferably be evaluated in vivo;
however, this hypothesis remains to be tested.
Conclusions
We have identified transcriptional targets that may be the
common endpoints of genetic alterations that are linked
to platinum resistance in ovarian tumors. The relative ex-
pression of these genes, either alone or in combination,
could serve as biomarkers of prognosis and platinum
resistance. In addition, the expression of these genes is
connected to the CSC phenotype. Therefore, the measure-
ment of CSC-related factors in ovarian tumors has
emerged as a new method of detecting platinum resist-
ance, even though the expression of the CSC markers is
heterogeneous among the different resistant tumors.
Finally, our results in vitro show that the inhibition of
druggable CSC-related targets sensitizes CSC-enriched
tumorspheres to platinum therapies, suggesting a new al-
ternative for the treatment of patients with platinum-
resistant ovarian cancer.
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